Allergy Therapy: From Antihistamines to Immunotherapy
Allergy therapy is an umbrella term covering four treatment categories: environmental control and avoidance, pharmacotherapy (antihistamines, intranasal steroids, leukotriene antagonists), allergen immunotherapy (SCIT injections or SLIT drops — the only disease-modifying options), and biologics (Xolair, Dupixent, Tezspire) for asthma comorbidity. Only immunotherapy retrains the immune system at the allergen-specific level, producing durable remission after a 3-to-5-year course.
6 peer-reviewed sources
Allergy therapy encompasses multiple treatment types; only SCIT and SLIT (sublingual immunotherapy) are disease-modifying — they induce allergen-specific immune tolerance, unlike pharmacotherapy or biologics, which suppress symptoms without modifying the underlying sensitization.
The essentials
Allergy therapy is the broadest umbrella term in the allergy treatment landscape — and using it correctly requires understanding a structured decision ladder, not collapsing it onto a single modality. The AAAAI/ACAAI Joint Task Force on Practice Parameters for allergic rhinitis organizes therapy as: environmental control → second-generation oral antihistamines → intranasal corticosteroids → combination pharmacotherapy → allergen immunotherapy (SCIT or SLIT) → biologics for asthma comorbidity.
Each rung of the ladder has a different mechanism, time horizon, and disease-modifying potential:
Pharmacotherapy (antihistamines, intranasal corticosteroids, leukotriene receptor antagonists) provides symptom control within hours to weeks but offers no benefit after stopping. Second-generation oral antihistamines (cetirizine, loratadine, fexofenadine) act within approximately one hour. Intranasal corticosteroids reach peak benefit in 1-2 weeks. These treatments are appropriate first-line options for mild-to-moderate symptoms.
Allergen immunotherapy — SCIT or SLIT — is the only allergy-specific disease-modifying therapy currently in clinical use per Cox 2011 Practice Parameter (DOI 10.1016/j.jaci.2010.09.034). SCIT and SLIT take 1-3 years to demonstrate full disease-modifying effect and produce remission persisting years after stopping (Durham SR et al., N Engl J Med 1999;341:468-475). In children, a 3-year SCIT course reduced the risk of developing asthma 4.6-fold at 10-year follow-up (Jacobsen L et al., Allergy 2007, PAT study, adjusted OR 4.6, 95% CI 1.5-13.7) — an effect no pharmacotherapy produces.
Curex's at-home IgE blood test with allergist consultation identifies which allergens are clinically relevant and whether immunotherapy is an appropriate next step or whether pharmacotherapy alone is sufficient.
Biologics (Xolair/omalizumab, Dupixent/dupilumab, Tezspire/tezepelumab) are appropriate for severe allergic asthma, atopic dermatitis, and chronic urticaria but do not modify allergen-specific sensitization — they block inflammatory pathways downstream of allergen exposure. Benefits return after stopping.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
Among allergy therapy options, only SCIT and SLIT are disease-modifying — benefits persist after the treatment course ends. Cochrane meta-analysis (Calderón 2007) found SCIT symptom SMD -0.73 across 51 RCTs. Pharmacotherapy achieves similar short-term symptom control but no long-term remission.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
The allergy therapy decision matrix maps symptom severity and patient circumstances to the appropriate treatment rung.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
SCIT (Allergy Shots) | |||||
SLIT Drops | |||||
Intranasal Corticosteroids | |||||
Biologics (Xolair/Dupixent/Tezspire) |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
For patients ready for disease-modifying allergy therapy, Curex offers at-home subcutaneous immunotherapy — the SCIT shot itself — as one weekly self-administered injection for $129/month. The personalized serum is sterile-compounded to USP <797> standards and overseen by a board-certified allergist; the first dose and every dose change are supervised live over Zoom and a prescribed epinephrine auto-injector is confirmed on hand, so eligible maintenance patients skip the weekly clinic visits without giving up the disease-modifying course.
See if at-home shots are right for youFrequently asked questions
What is the most effective allergy therapy?
Among currently available allergy therapies, subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are the most effective long-term options for IgE-mediated allergic rhinitis because they are disease-modifying. Cochrane meta-analysis of SCIT (Calderón MA et al., 2007, 51 RCTs / 2,871 patients) found a symptom SMD of -0.73. For acute symptom relief, intranasal corticosteroids achieve approximately 32% symptom reduction and are the most effective single pharmacotherapy for nasal symptoms. The right answer depends on the patient's diagnosis, severity, comorbidities, and ability to commit to a multi-year course. A board-certified allergist can determine which therapy fits based on IgE sensitization and clinical picture.
Is allergy therapy permanent?
No allergy therapy is permanently curative, but SCIT and SLIT are the closest to durable disease modification. Durham SR et al. (N Engl J Med 1999;341:468-475) demonstrated that grass-pollen SCIT remission persisted for years after a 3-4 year course ended. Children completing SCIT courses showed 4.6-fold improved odds of avoiding asthma at 10-year follow-up (Jacobsen L et al., Allergy 2007 PAT study). Some patients require retreatment after 5-10 years if symptoms recur. Pharmacotherapy provides no lasting benefit after stopping. Biologics suppress disease but do not modify the underlying sensitization.
How long does allergy therapy take?
The time horizon depends on the therapy. Antihistamines act within one hour; intranasal corticosteroids reach peak benefit in 1-2 weeks. SCIT requires 3-6 months of weekly build-up injections to reach maintenance, then 3-5 years of maintenance visits every 2-4 weeks — approximately 60-80+ clinic visits total. SLIT drops require 3-5 years of daily sublingual administration. Biologics require ongoing injections every 2-4 weeks with no defined endpoint. Disease-modifying benefit from immunotherapy typically becomes noticeable within 3-6 months of reaching maintenance and consolidates fully over 1-3 years.
Can allergy therapy prevent asthma?
Allergen immunotherapy (SCIT and SLIT) is the only allergy therapy with evidence for preventing the progression from allergic rhinitis to asthma. Jacobsen L et al. (Allergy 2007, PAT 10-year follow-up) found SCIT-treated children had an adjusted OR of 4.6 (95% CI 1.5-13.7) for asthma prevention versus controls. Möller C et al. (J Allergy Clin Immunol 2002) also demonstrated asthma prevention with sublingual immunotherapy in allergic children. Pharmacotherapy (antihistamines, intranasal steroids) does not prevent asthma development. Biologics treat existing asthma but have not demonstrated prevention of asthma onset from allergic rhinitis.
What is the difference between allergy therapy and allergy medication?
Allergy medication (pharmacotherapy) suppresses allergic symptoms by blocking histamine receptors (antihistamines), reducing mucosal inflammation (intranasal corticosteroids), or blocking leukotriene receptors (montelukast). These medications treat symptoms but do not modify the underlying immune sensitization — benefits stop when medication stops. Allergy therapy, in its disease-modifying sense, means allergen immunotherapy (SCIT or SLIT), which retrains the immune system to tolerate the specific allergen over a 3-to-5-year course, producing remission that persists years after stopping treatment. The distinction matters clinically: a patient asking about 'allergy therapy' may have very different expectations depending on whether they expect symptom relief or immune reprogramming.
Does allergy therapy work for food allergies?
SCIT (subcutaneous immunotherapy) is NOT standard of care for food allergies. Oral immunotherapy (OIT) has been investigated for peanut and other food allergens. Palforzia (peanut OIT) was FDA-approved in January 2020 based on the PALISADE trial, but as of generation date it is being withdrawn from the commercial market on July 31, 2026. Off-label OIT through specialized food-allergy clinics remains an option. Xolair (omalizumab) received an FDA indication for reducing allergic reactions from IgE-mediated food allergies on February 16, 2024 (OUtMATCH trial: 67% protection vs 7% placebo). For food allergy therapy, patients should consult a board-certified allergist or food-allergy specialist.
Is allergy therapy covered by insurance?
Coverage depends on the therapy type. SCIT (allergy shots) is typically covered under major medical insurance with standard allergist billing codes (CPT 95115, 95117, 95165 per CMS Article A57472). Biologics (Xolair, Dupixent, Tezspire) are typically covered under specialty pharmacy benefit with prior authorization. Pharmacotherapy (antihistamines, intranasal steroids) is covered under pharmacy benefits; many options are available OTC without a prescription. SLIT drops are off-label and often not covered by insurance, though some patients receive reimbursement depending on their plan. Medicaid acceptance by allergists varies from 13.4% to 72.3% by state (Ho FO et al., Am J Manag Care 2024).
Related Articles
Allergy Shot Name: SCIT Defined & Explained | Curex
The clinical name for an allergy shot is subcutaneous immunotherapy (SCIT). There is no single brand name — each vial is custom-compounded. SLIT tablets have brand names; SCIT does not.
Read moreWeekly Allergy Shots: Schedule & Missed Doses | Curex
Weekly allergy shots are the conventional SCIT build-up: 24–28 visits over 3–6 months. Learn the dose ladder, missed-dose rules per Cox 2011, and why 23.9% drop out.
Read moreAllergy Shots for Pollen: Who Qualifies | Curex Guide
Yes, allergy shots target pollen via SCIT. Cox 2011 candidacy threshold, FDA SLIT tablets, per-allergen efficacy, and Curex at-home shots — all covered.
Read moreAllergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreAllergy Test Shots vs Treatment: CPT Codes | Curex
Allergy test shots (CPT 95004 prick, CPT 95024 intradermal) diagnose sensitization in one visit. Treatment shots (SCIT, CPT 95115/95117) are a 3-5 year immunotherapy course.
Read moreInjectable Allergy Medication – SCIT, Biologics, Steroids & Epinephrine
Injectable allergy medications include SCIT (no brand name), Xolair, Dupixent, Tezspire, Kenalog, Depo-Medrol, and EpiPen. Discover which is the only disease-modifying option and why SCIT isn't a conventional drug. FDA approval dates included.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.